Zymeworks, Jazz Pharmaceuticals Shares Rise Following Positive Phase 3 Results for Cancer Treatment

Zymeworks and Jazz Pharmaceuticals shares surged after announcing positive Phase 3 trial results for their cancer treatment, zanidatamab-hrii. Zymeworks' stock rose 59% to $29.45, while Jazz Pharmaceuticals' stock increased 31% to $184.99. The treatment, used with chemotherapy for HER2-positive gastroesophageal adenocarcinoma, showed a consistent safety profile. The companies plan to submit a supplemental biologics license application in 2026. The treatment is already approved for second-line biliary tract cancer under the name Ziihera.